$ACH

Accendra Health Inc (ACH) reported a 1% revenue decline in Q3 2026, its first annual drop, with adjusted EBITDA at $47.8M. Full-year adjusted EBITDA may be 30% below prior guidance. The company lost market share in sleep and respiratory, and faces operational challenges. Management expects to resolve commercial payer audit issues by Q4 2026 and outlined a turnaround plan for 2027. Net debt is $1.73B, with strong liquidity.

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 29, 2026, Perry A. Bernocchi, the Company’s Executive Vice President, Chief Operating Officer, entered into a tr

Accendra Health (ACH) extended its receivables sale program to October 2029, keeping the $150M size unchanged. ACH shares rose nearly 21% premarket to $0.31.

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029 ​ ​ Richmond, VA – November 2, 2026 – Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Rece

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders’ Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard ​ RICHMOND, VA – October 30, 2026 – Accendra Health, Inc

Accendra Health (ACH) received an NYSE notice for failing to meet $50M market cap and equity requirements. The company plans to submit a business plan within 45 days to address the issue. According to the NYSE, the stock remains listed during this period.

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard ​ RICHMOND, VA – October 9, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6,

Accendra Health (ACH) received a NYSE notice for its stock price averaging below $1 over 30 days. The company has six months to address the issue, potentially through a reverse stock split, while shares remain listed.

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth ​ Gardner-Smith to Succeed Ed Pesicka Following Previously Announced Retirement ​ Company Announces Scott Lloyd as Chief Commercial Offic

Accendra Health (ACH) reported Q2 2026 revenue of $613.2M, down from $681.9M YoY, and adjusted EBITDA of $60.1M, down from $96.6M. The company revised full-year revenue guidance to $2.45B-$2.55B and adjusted EBITDA to $300M-$320M, citing slower growth and collection rate issues. Total debt decreased by $385M to $1.72B. CEO Edward Pesicka announced his retirement by year-end.